ArticleScientific reports2025
Emodin influences pyroptosis-related Caspase 1-GSDMD axis alleviated cerebral ischemia-reperfusion injury in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cell death in ischemia-reperfusion injury: beyond a single-cell-death perspective.Biomarker research · 2026Review
- LncRNA-XIST Competitively Binds to MicroRNA-532-5p to Regulate PTEN Expression, Exacerbating Cerebral Ischemia-Reperfusion Injury.Advanced biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cerebrovascular diseases, particularly ischemic stroke, are a leading cause of global disability. Effective management of ischemia-reperfusion injury is crucial in stroke treatment. Emodin, known for its anti-inflammatory and neuroprotective properties, has been shown to protect against ischemia-reperfusion injury by modulating pyroptosis. However, the molecular mechanisms underlying its effects in cerebral ischemia-reperfusion injury are not well understood. This study aims to investigate the neuroprotective mechanisms of Emodin in ischemic stroke. SD rats were randomly assigned to different groups: control, sham, model, and Emodin intervention groups with varying dosages. Cerebral ischemia-reperfusion injury was induced using the middle cerebral artery occlusion (MCAO) method, and Emodin (10 mg/kg, 20 mg/kg, 40 mg/kg) was administered intraperitoneally. Neurological deficits were evaluated using the modified Neurological Severity Score (mNSS), and infarct volume was assessed via TTC staining. Pathomorphological changes were observed using HE staining. Protein expression levels associated with pyroptosis, including NLRP3, Caspase 1, and GSDMD, were analyzed by Western blotting and immunofluorescence. The levels of IL-1β and IL-18 were measured using ELISA (Caspase 1 indicates cleaved Caspase 1, GSDMD indicates the active pro-forms of GSDMD, used throughout). Emodin exhibits significant beneficial effects in improving neurological deficits caused by cerebral ischemia-reperfusion injury. It effectively reduces the ratio of infarct volume, alleviates cytopathic damage, and suppresses the expression of pyroptosis-related proteins, including NLRP3, Caspase 1, Caspase 1, and GSDMD. Furthermore, Emodin decreases the levels of pro-inflammatory cytokines IL-1β and IL-18, thus attenuating the inflammatory response. The expression of pyroptosis-related proteins is upregulated in rats after cerebral ischemia-reperfusion injury. Emodin demonstrates neuroprotective effects against cerebral ischemia-reperfusion injury in rats, potentially by modulating the expression of pyroptosis-related proteins mediated through the Caspase 1-GSDMD axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.